Article

New antibiotics to draw interest for ophthalmologists

With the recent FDA approvals of fourth-generation fluoroquinolones,ophthalmologists now have two new antibiotics to fight bacteria in the eye.Moxifloxacin (Vigamox, Alcon), approved April 16, and gatifloxacin (Zymar,Allergan), approved March 31, are the latest therapies for the treatmentof bacterial conjunctivitis caused by susceptible strains of bacteria.At this year's ARVO meeting, ophthalmologists can gain knowledge andclinical information about the fourth-generation fluoroquinolones throughthe various clinical studies that will presented. In a session entitled"New Antibiotics," seven papers will focus exclusively on theclinical studies associated with these two drugs (Program #2114-#2120).

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
Brett Bielory, MD, discusses his poster at the ASCRS annual meeting, which focuses on an under-diagnosed corneal pathology: neurotrophic keratitis.
© 2025 MJH Life Sciences

All rights reserved.